Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab with High-dose Ibrutinib for CLL/SLL Progressing on Ibrutinib
NCT02611908Phase 1Withdrawn
- Start
- Jun 2016
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib and obinutuzumab in chronic lymphocytic leukemia (CLL). Primary endpoint: Maximum Tolerated Dose at 2 months. Planned start Jun 2016; status: withdrawn.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02611908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611908.